Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept

Sacher, Christopher; Rubbert, A.; König, Cathrin; Scharffetter‐­Kochanek, Karin; Krieg, Thomas; Hunzelmann, Nicolas

doi:10.1067/mjd.2001.119100

Cited by 99 publications

(46 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Research in MMP characterising its autoantibody profile supports the potential use of monoclonal antibodies. There are reports describing the successful use of anti-TNF-a therapies 4,5 and daclizumab (reviewed in Lim et al 3 ).…”

Section: Case Reportmentioning

confidence: 99%

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-α

Hyttel

Whallett

Quinlan

2007

Eye

View full text Add to dashboard Cite

Section: Case Reportmentioning

confidence: 99%

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-α

Hyttel

Whallett

Quinlan

2007

Eye

View full text Add to dashboard Cite

“…74,75 There have been a few reports of successful use of TNFα inhibitors in MMP. [76][77][78][79][80][81][82] Etanercept can be effective in controlling severe MMP cases in patients who fail conventional immunosuppressive agents, but controlled trials are absent. Etanercept can be considered as an off-label alternative treatment for patients with MMP who would require aggressive immunosuppressive regimens.…”

Section: Methotrexate (Mtx)-oralmentioning

confidence: 99%

Mucous membrane pemphigoid

Sollecito

Parisi

2005

Dental Clinics of North America

View full text Add to dashboard Cite

“…Otros tratamientos referidos recientemente con resultados satisfactorios en casos aislados son la talidomida (100 mg/día) 20 , el etanercept (25 mg/2 veces a la semana/subcutánea-mente) 21 , o la asociación de nicotinamida y tetraciclina 22 . En relación al pronóstico de los pacientes, se ha observado que depende de los lugares afectados.…”

Section: Bunclassified

Penfigoides: Revisión y puesta al día

Milián-Masanet

Sanchis-Bielsa

2004

RCOE

View full text Add to dashboard Cite

Resumen: Las enfermedades vesículo-ampollares de la mucosa oral pueden estar producidas por agentes mecánicos, físicos o químicos, por microorganismos, o por desórdenes inmunológicos o alérgicos. Dentro de los procesos ampollares de base inmunológica se encuentran el eritema exudativo multiforme, el pénfigo vulgar, el penfigoide, el liquen plano, el lupus eritematoso, la dermatitis herpetiforme y la enfermedad por depósito lineal de IgA. Este artí-culo presenta una revisión de los diferentes aspectos etiopatogénicos, clínicos, y terapéuticos de los penfigoides dentro de las enfermedades ampollares de la cavidad oral. Además se realiza una puesta al día, exponiendo los criterios diagnósticos, así como las técnicas más importantes empleadas en el mismo. A review is provided of the different etiopathogenic, clinical and therapeutic aspects of pemphigoid disorders among the range of ampullar diseases of the oral cavity. An update is also provided, with a description of the diagnostic criteria and principal techniques employed. Milián-Masanet MA, Sanchis-Bielsa JM. Penfigoides: revisión y puerta al día.

show abstract

Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor α antagonist etanercept

Cited by 99 publications

References 12 publications

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-α

Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-α

Mucous membrane pemphigoid

Penfigoides: Revisión y puesta al día

Contact Info

Product

Resources

About